Dermal Fillers
ELLANSÉ references stocked by ALLPARA for professional use, sourced direct and certified on every shipment.
CE Marked
SKU 10368
Ellansé S
Ellansé S is an injectable solution for subdermal facial implantation that stimulates collagen. It provides immediate volume and progressive, long-lasting collagen-driven contour support.
In stock
Volume
2 x 1 mL
Laboratory
Sinclair Pharma
Origin
Netherlands
Indication
Facial volume loss and contour correction
Trade price and history are verified-only
allpara supplies licensed practitioners. Sign in or apply for a B2B account to see live pricing, volume tiers and price history.
Ellansé S is a sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent injectable implant, indicated for subdermal implantation in the face for the lasting correction of wrinkles and facial ageing signs or conditions. Its principal component is synthetic Poly-e-caprolactone (PCL) microspheres suspended in a carrier gel of phosphate buffered saline, glycerin and carboxymethylcellulose (CMC), in a ratio of 30% PCL microspheres to 70% gel carrier.
The CMC-based gel provides immediate filling of areas affected by volume loss and is resorbed 2 to 3 months after injection, after which the PCL microspheres are progressively replaced by the patient's own collagen, predominantly type I, rebuilding and reshaping facial contours over time. Ellanse S is the option recommended for minimal volume augmentation. Practitioners weighing Ellanse S vs M are choosing the degree of correction as well as the longevity: S offers 18 months against 24 months for M, a difference that comes from the shorter PCL chain length in the S microspheres.
Ellansé S is supplied as 2 x 1 mL ready-to-use syringes with four 27G needles in the pack, and is a Class III medical device CE marked since 2009 under Medical Device Directive 93/42/EEC. ALLPARA supplies it to clinics and licensed practitioners with batch-level traceability and documentation available on request. Wholesale pricing is available to registered professional buyers.
Key Benefits of Ellansé S
- Immediate volumising effect from the carboxymethylcellulose carrier gel, which fills areas affected by volume loss and is resorbed 2 to 3 months after injection
- Progressive stimulation of the patient's own collagen, predominantly type I, by the polycaprolactone microspheres
- 30% PCL microspheres to 70% CMC-based carrier gel, with a microsphere diameter of approximately 100 microns
- 18 months of longevity, against 24 months for Ellanse M, the two being distinguished only by the initial polymer chain length of the PCL
- 90% of patients treated with Ellanse S or M had improved, much improved or very much improved results at 12 months
- The intended option for more conservative, minimal volume augmentation within the Ellanse family, which makes it a reasonable starting point for a patient new to collagen stimulators
- Treats upper, mid and lower face: forehead, temples, brow, nose, cheeks, nasolabial folds, oral commissures, marionette lines, chin and jawline
- Sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent
- Supplied as 2 x 1 mL ready-to-use syringes with four 27G needles
- Class III medical device, CE marked since 2009, legal manufacturer AQTIS Medical B.V., Utrecht, Netherlands, for Sinclair
Indications and Professional Use
Main indications
- Subdermal implantation in the face for the lasting correction of wrinkles and facial ageing signs or conditions
- Correction of age-related volume loss due to increased skin laxity, fat loss and diminished support from underlying muscle and bone
- Minimal volume augmentation, which is the position of Ellanse S within the range
Professional use
This product is supplied for administration by qualified medical practitioners only, within the scope of their professional registration and local regulations for injectable medical devices. It is a stand-alone device and is not required to be used in combination with any other device to meet its intended purpose. Injection technique, plane and volume are determined by the treating practitioner on a per-patient basis, with the approach depending on the facial region, the depth of implantation and the desired degree of volume correction. Selection between Ellanse S and Ellanse M is a decision about the degree of correction and the longevity required, and the two must not be treated as interchangeable. Each unit is sterile and for single use only.
Treatment areas
- Upper face: forehead, temples, brow area
- Mid face: nose reshaping, cheek augmentation, nasolabial folds
- Lower face: oral commissures, marionette lines, chin definition, jawline
- Injected subdermally, into the subcutaneous fat or hypodermis, with modalities recommended per facial region and per area
Patient profile
Intended for adult patients over 18 who are not pregnant or breast-feeding and who are deemed appropriate for treatment by the physician. Because polycaprolactone is a bioresorbable implant rather than a hyaluronic acid gel, patient selection and expectation setting carry additional weight and are determined by the practitioner at consultation. Contraindications, warnings and precautions must be reviewed in the product leaflet before treatment.
How Ellansé S Works
Ellansé S works through two components. The carboxymethylcellulose gel provides immediate filling of areas affected by volume loss and is resorbed 2 to 3 months after injection. The polycaprolactone microspheres, approximately 100 microns in diameter, are then progressively replaced by the patient's own collagen, predominantly type I, which rebuilds facial support and contour over time and produces the progressive refinement seen after the initial fill.
Implantation is subdermal, with the approach depending on the facial region, the depth of implantation and the desired degree of volume correction. Within the range, Ellanse S is recommended for minimal volume augmentation while Ellanse M is intended for more extensive augmentation, so the two are not interchangeable on volume any more than on longevity. S lasts 18 months against 24 months for M, and that difference comes from the chain length, or molecular weight, of the PCL chains within the microspheres: the shorter chains in the S variant degrade sooner.
Why Order From Allpara
Allpara offers genuine, verified ELLANSÉ products from vetted suppliers, with full batch-traceability and expert support. We serve clinics and aesthetic professionals with CE-certified products, fast EU-wide delivery from our EU warehouse, and competitive trade pricing. Our focus is your patients' safety, satisfaction and results - with dedicated after-sales support for your peace of mind.
Frequently Asked Questions
Ellanse S vs M: which should a clinic stock?
Both are the same polycaprolactone collagen stimulator platform, supplied at different longevities: 18 months for S and 24 months for M. The difference comes from the chain length, or molecular weight, of the PCL chains within the microspheres, with the shorter chains in S degrading sooner. S is positioned for minimal volume augmentation and M for more extensive augmentation. Both are supplied as 2 x 1 mL, so clinics commonly hold both and match the variant to the patient.
How long does Ellansé S last?
Ellansé S offers 18 months of longevity. Duration varies with the individual patient, the area addressed, the volume placed and the injection technique used.
What is Ellansé S made of?
Ellansé S is 30% synthetic Poly-e-caprolactone microspheres, approximately 100 microns in diameter, suspended in a 70% carrier gel of phosphate buffered saline, glycerin and carboxymethylcellulose. It is sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent. The carrier gel is resorbed 2 to 3 months after injection and is progressively replaced by the patient's own collagen, predominantly type I.
More from Sinclair
LANLUMA references stocked by ALLPARA for professional use, sourced direct and certified on every shipment.
LANLUMA Products
View all 2
MAILI references stocked by ALLPARA for professional use, sourced direct and certified on every shipment.
MAILI Products
View all 4
PERFECTHA references stocked by ALLPARA for professional use, sourced direct and certified on every shipment.
PERFECTHA Products
View all 8
SILHOUETTE SOFT references stocked by ALLPARA for professional use, sourced direct and certified on every shipment.
SILHOUETTE SOFT Products
View all 2
Needle, Cannulas & Threads
Clinic alternatives
/ Recently viewed
Pick up where you left off
Ellansé S
In stock
CE Marked
Ellansé S is a sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent injectable implant, indicated for subdermal implantation in the face for the lasting correction of wrinkles and facial ageing signs or conditions. Its principal component is synthetic Poly-e-caprolactone (PCL) microspheres suspended in a carrier gel of phosphate buffered saline, glycerin and carboxymethylcellulose (CMC), in a ratio of 30% PCL microspheres to 70% gel carrier.
The CMC-based gel provides immediate filling of areas affected by volume loss and is resorbed 2 to 3 months after injection, after which the PCL microspheres are progressively replaced by the patient's own collagen, predominantly type I, rebuilding and reshaping facial contours over time. Ellanse S is the option recommended for minimal volume augmentation. Practitioners weighing Ellanse S vs M are choosing the degree of correction as well as the longevity: S offers 18 months against 24 months for M, a difference that comes from the shorter PCL chain length in the S microspheres.
Ellansé S is supplied as 2 x 1 mL ready-to-use syringes with four 27G needles in the pack, and is a Class III medical device CE marked since 2009 under Medical Device Directive 93/42/EEC. ALLPARA supplies it to clinics and licensed practitioners with batch-level traceability and documentation available on request. Wholesale pricing is available to registered professional buyers.
Key Benefits of Ellansé S
- Immediate volumising effect from the carboxymethylcellulose carrier gel, which fills areas affected by volume loss and is resorbed 2 to 3 months after injection
- Progressive stimulation of the patient's own collagen, predominantly type I, by the polycaprolactone microspheres
- 30% PCL microspheres to 70% CMC-based carrier gel, with a microsphere diameter of approximately 100 microns
- 18 months of longevity, against 24 months for Ellanse M, the two being distinguished only by the initial polymer chain length of the PCL
- 90% of patients treated with Ellanse S or M had improved, much improved or very much improved results at 12 months
- The intended option for more conservative, minimal volume augmentation within the Ellanse family, which makes it a reasonable starting point for a patient new to collagen stimulators
- Treats upper, mid and lower face: forehead, temples, brow, nose, cheeks, nasolabial folds, oral commissures, marionette lines, chin and jawline
- Sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent
- Supplied as 2 x 1 mL ready-to-use syringes with four 27G needles
- Class III medical device, CE marked since 2009, legal manufacturer AQTIS Medical B.V., Utrecht, Netherlands, for Sinclair
Indications and Professional Use
Main indications
- Subdermal implantation in the face for the lasting correction of wrinkles and facial ageing signs or conditions
- Correction of age-related volume loss due to increased skin laxity, fat loss and diminished support from underlying muscle and bone
- Minimal volume augmentation, which is the position of Ellanse S within the range
Professional use
This product is supplied for administration by qualified medical practitioners only, within the scope of their professional registration and local regulations for injectable medical devices. It is a stand-alone device and is not required to be used in combination with any other device to meet its intended purpose. Injection technique, plane and volume are determined by the treating practitioner on a per-patient basis, with the approach depending on the facial region, the depth of implantation and the desired degree of volume correction. Selection between Ellanse S and Ellanse M is a decision about the degree of correction and the longevity required, and the two must not be treated as interchangeable. Each unit is sterile and for single use only.
Treatment areas
- Upper face: forehead, temples, brow area
- Mid face: nose reshaping, cheek augmentation, nasolabial folds
- Lower face: oral commissures, marionette lines, chin definition, jawline
- Injected subdermally, into the subcutaneous fat or hypodermis, with modalities recommended per facial region and per area
Patient profile
Intended for adult patients over 18 who are not pregnant or breast-feeding and who are deemed appropriate for treatment by the physician. Because polycaprolactone is a bioresorbable implant rather than a hyaluronic acid gel, patient selection and expectation setting carry additional weight and are determined by the practitioner at consultation. Contraindications, warnings and precautions must be reviewed in the product leaflet before treatment.
How Ellansé S Works
Ellansé S works through two components. The carboxymethylcellulose gel provides immediate filling of areas affected by volume loss and is resorbed 2 to 3 months after injection. The polycaprolactone microspheres, approximately 100 microns in diameter, are then progressively replaced by the patient's own collagen, predominantly type I, which rebuilds facial support and contour over time and produces the progressive refinement seen after the initial fill.
Implantation is subdermal, with the approach depending on the facial region, the depth of implantation and the desired degree of volume correction. Within the range, Ellanse S is recommended for minimal volume augmentation while Ellanse M is intended for more extensive augmentation, so the two are not interchangeable on volume any more than on longevity. S lasts 18 months against 24 months for M, and that difference comes from the chain length, or molecular weight, of the PCL chains within the microspheres: the shorter chains in the S variant degrade sooner.
Why Order From Allpara
Allpara offers genuine, verified ELLANSÉ products with full batch-traceability, CE-certified stock, fast EU-wide delivery and expert after-sales support.
Frequently Asked Questions
Ellanse S vs M: which should a clinic stock?
Both are the same polycaprolactone collagen stimulator platform, supplied at different longevities: 18 months for S and 24 months for M. The difference comes from the chain length, or molecular weight, of the PCL chains within the microspheres, with the shorter chains in S degrading sooner. S is positioned for minimal volume augmentation and M for more extensive augmentation. Both are supplied as 2 x 1 mL, so clinics commonly hold both and match the variant to the patient.
How long does Ellansé S last?
Ellansé S offers 18 months of longevity. Duration varies with the individual patient, the area addressed, the volume placed and the injection technique used.
What is Ellansé S made of?
Ellansé S is 30% synthetic Poly-e-caprolactone microspheres, approximately 100 microns in diameter, suspended in a 70% carrier gel of phosphate buffered saline, glycerin and carboxymethylcellulose. It is sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent. The carrier gel is resorbed 2 to 3 months after injection and is progressively replaced by the patient's own collagen, predominantly type I.
More from Sinclair
View laboratory →* Professional-use product. Packaging may vary by batch or market. Refer to the supplied IFU for full directions and contraindications.